Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Allelic polymorphisms of KIRs and antitumor immunity against chronic myeloid leukemia.

Immunological medicine - 1 Jun 2021

Shindo Takero, Ureshino Hiroshi, Kojima Hiroto, Tanaka Hidenori, Kimura Shinya

Abstract excerpt

The development of BCR-ABL1 tyrosine kinase inhibitors (TKIs) markedly improved the prognosis of patients with chronic myeloid leukemia (CML). Approximately 50% of patients who achieve deep molecular response (DMR) remain in treatment-free remission (TFR) even after discontinuation of TKIs. Although TKIs may achieve clinical "cure" after TKI treatment for specific periods, there are no reliable biomarkers for...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Fusion Proteins, bcr-abl
Share to High-Throughput Nucleotide Sequencing

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Killer Cells, Natural

Share to Leukemia, Myelogenous, Chronic, BCR-ABL Positive

Share to Protein Kinase Inhibitors

Share to Protein-Tyrosine Kinases

Share to Receptors, KIR

Share to Treatment Outcome

Source

Identifiers

PMID: 32715973
DOI: 10.1080/25785826.2020.1796062

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Allelic polymorphisms of KIRs and antitumor immunity against chronic myeloid leukemia.PMID 32715973Read ↗

Allelic Polymorphisms of KIRs and HLAs Predict Favorable Responses to Tyrosine Kinase Inhibitors in CML.Semantic proximity Read ↗

Certain Killer Immunoglobulin-Like Receptor (KIR)/KIR HLA Class I Ligand Genotypes Influence Natural Killer Antitumor Activity in Myelogenous Leukemia but Not in Acute Lymphoblastic Leukemia: A Case Control Leukemia Association StudySemantic proximity Read ↗

Natural killer cell receptors and ligand variants modulate response to tyrosine kinase inhibitors in patients with chronic myeloid leukemia.Semantic proximity Read ↗

Homozygosity for killer immunoglobin-like receptor haplotype A predicts complete molecular response to treatment with tyrosine kinase inhibitors in chronic myeloid leukemia patients.Semantic proximity Read ↗

Influence of Killer Immunoglobulin-Like Receptors and Somatic Mutations on Transplant Outcomes in Acute Myeloid Leukemia.Semantic proximity Read ↗

KIR2DL5B genotype predicts outcomes in CML patients treated with response-directed sequential imatinib/nilotinib strategy.Semantic proximity Read ↗

Association of killer cell immunoglobulin-like receptors and their cognate HLA class I ligands with susceptibility to acute myeloid leukemia in Iranian patients.Semantic proximity Read ↗

KIR-HLA profiling shows presence of higher frequencies of strong inhibitory KIR-ligands among prognostically poor risk AML patients.Semantic proximity Read ↗

Can we make a better match or mismatch with KIR genotyping?Semantic proximity Read ↗

Large case-control study indicates no association of KIR genotype and risk of developing acute myeloid leukemia.Semantic proximity Read ↗

Activating KIR3DS1: A key driver of KIR3DL1/HLA-Bw4-linked risk in CML.Semantic proximity Read ↗

Killer-cell immunoglobulin-like receptor genes and ligands and their role in hematologic malignancies.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.